Royal Bank Of Canada Lowers ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target to $30.00

ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target reduced by investment analysts at Royal Bank Of Canada from $31.00 to $30.00 in a report released on Thursday,Benzinga reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s target price would indicate a potential upside of 22.15% from the stock’s previous close.

Several other research analysts have also recently weighed in on the stock. Mizuho upgraded shares of ACADIA Pharmaceuticals from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $29.00 to $35.00 in a report on Monday. Wall Street Zen downgraded ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. Piper Sandler set a $37.00 price target on ACADIA Pharmaceuticals in a research report on Tuesday, December 16th. Oppenheimer reiterated a “market perform” rating on shares of ACADIA Pharmaceuticals in a report on Friday, February 6th. Finally, Citigroup boosted their price objective on ACADIA Pharmaceuticals from $33.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $30.74.

ACADIA Pharmaceuticals Stock Down 0.3%

Shares of NASDAQ:ACAD opened at $24.56 on Thursday. The business’s 50 day moving average is $25.53 and its 200 day moving average is $24.45. ACADIA Pharmaceuticals has a 12-month low of $13.40 and a 12-month high of $28.35. The stock has a market cap of $4.16 billion, a price-to-earnings ratio of 10.72, a PEG ratio of 8.72 and a beta of 0.66.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating the consensus estimate of $0.12 by $1.48. The business had revenue of $298.00 million for the quarter, compared to analysts’ expectations of $292.54 million. ACADIA Pharmaceuticals had a return on equity of 13.96% and a net margin of 36.49%.The business’s revenue was up 9.4% on a year-over-year basis. During the same period last year, the business earned $0.86 EPS. As a group, equities research analysts expect that ACADIA Pharmaceuticals will post 0.7 earnings per share for the current year.

Insider Activity at ACADIA Pharmaceuticals

In other news, EVP Jennifer J. Rhodes sold 6,950 shares of the firm’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $23.38, for a total value of $162,491.00. Following the completion of the transaction, the executive vice president directly owned 7,609 shares of the company’s stock, valued at $177,898.42. This trade represents a 47.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 26.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Braidwell LP purchased a new position in ACADIA Pharmaceuticals during the 3rd quarter valued at about $50,760,000. Marshall Wace LLP lifted its holdings in shares of ACADIA Pharmaceuticals by 496.2% in the second quarter. Marshall Wace LLP now owns 1,969,711 shares of the biopharmaceutical company’s stock worth $42,487,000 after buying an additional 1,639,315 shares in the last quarter. Norges Bank bought a new position in shares of ACADIA Pharmaceuticals in the fourth quarter valued at approximately $40,266,000. Millennium Management LLC grew its stake in ACADIA Pharmaceuticals by 2,052.1% during the third quarter. Millennium Management LLC now owns 1,483,235 shares of the biopharmaceutical company’s stock valued at $31,652,000 after acquiring an additional 1,414,315 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its holdings in ACADIA Pharmaceuticals by 390.1% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,648,864 shares of the biopharmaceutical company’s stock worth $35,187,000 after acquiring an additional 1,312,426 shares during the period. Institutional investors own 96.71% of the company’s stock.

Key Headlines Impacting ACADIA Pharmaceuticals

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: Q4 beat and upgraded 2026 revenue outlook — ACAD reported stronger-than-expected Q4 results (EPS beat) and a milestone year with >$1B in revenue, and guided 2026 revenue to $1.22B–$1.28B, driven by NUPLAZID and DAYBUE. This underpins growth expectations for the company. Acadia Reports Q4 & Full Year 2025 Results
• Positive Sentiment: Analyst price-target upgrades — Several firms raised targets after the quarter (TD Cowen to $37 and Citizens JMP to $35), reflecting confidence in commercial momentum for DAYBUE and NUPLAZID. Benzinga coverage of analyst moves
• Neutral Sentiment: Minor analyst downtick but still constructive — Royal Bank of Canada trimmed its target to $30 but keeps an “outperform” view; this is a modest adjustment rather than a directional reversal. Benzinga: RBC target change
• Neutral Sentiment: Short-interest data appears anomalous — February short-interest entries show 0 shares / NaN increases and 0.0 days-to-cover, indicating a data/reporting glitch rather than a real shift in short positioning.
• Negative Sentiment: Analyst EPS cuts from HC Wainwright — HC Wainwright trimmed Q3 and Q4 2026 EPS estimates (Q3: $0.16 from $0.24; Q4: $0.23 from $0.27), which can pressure near-term expectations despite a buy rating and $37 target.
• Negative Sentiment: Some sell-side caution — Stifel lowered its target to $24 and moved to a “hold,” a more conservative stance that adds selling pressure versus the upgrades. Benzinga: Stifel target change
• Negative Sentiment: Pipeline/regulatory and sales nuances — Coverage noted a sales miss in places and an EU setback for trofinetide that clouds parts of the growth narrative even as core brands accelerate. Zacks: Q4 recap and trofinetide outlook

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.